Dee Sparacio
@womenofteal.bsky.social
1.1K followers
330 following
64 posts
Ovarian Cancer Survivor , cancer research advocate, #GYNCSM community cofounder , blogger
Posts
Media
Videos
Starter Packs
Pinned
Reposted by Dee Sparacio
Reposted by Dee Sparacio
Reposted by Dee Sparacio
Dee Sparacio
@womenofteal.bsky.social
· Aug 28
Surgical and Blood-Based Minimal Residual Disease in Patients with Ovarian Cancer after First-line Therapy: Clinical Outcomes and Translational Opportunities
AbstractPurpose:. Minimal residual disease (MRD) after first-line treatment of advanced-stage ovarian cancer remains a long-standing barrier to cure. We investigated the prognostic and translational v...
aacrjournals.org
Reposted by Dee Sparacio
OncLive
@onclive.bsky.social
· Jul 11
Dostarlimab Plus Chemo Prolongs Time to First, Second Subsequent Therapy Regardless of Age in Endometrial Cancer
After 3 years of follow-up, dostarlimab plus chemotherapy was effective and tolerable in patients aged 70 years or older with endometrial cancer.
www.onclive.com
Dee Sparacio
@womenofteal.bsky.social
· Jul 12
Reposted by Dee Sparacio
Reposted by Dee Sparacio
Lisa MG, RN
@lmg622.bsky.social
· Jul 11
Upfront Radical Cytoreductive Surgery Extends Progression-Free Survival in Advanced Ovarian Cancer
The TRUST trial is the first phase III randomized study to show improved progression-free survival for primary cytoreductive surgery compared with interval surgery without compromising short-term or l...
ascopost.com
Reposted by Dee Sparacio